Regulada
- Nivel de riesgo
- Alto
- Riesgo-rentabilidad
- Muy mala
- Desde
- €250
La financiación está cerrada. La página sigue disponible como referencia; abajo verá proyectos abiertos similares.
Biogener
Italia
Biogenera is a Bologna biotech that has spent 17 years developing a new type of cancer drug that switches off a gene (MYCN) which drives some of the most aggressive childhood tumours; it wants to prove the drug in a first human trial and then license it to a large pharmaceutical company.
Cifras clave
- Rentabilidad estimada
- 5–7×
- estimación de la plataforma
- Valoración
- €89,952,077
- Participación ofrecida
- 0,3%
- Desde
- €576
- Objetivo
- €249,984
Qué posee, cómo puede dar rentabilidad y cuándo
¿Qué poseo?
0,3% de la empresa
Consulte en los documentos cómo se mantienen las participaciones y qué derechos otorgan.
¿Cómo puede dar rentabilidad?
La plataforma estima 5–7×
Normalmente solo si la empresa se vende o sale a bolsa. Las estimaciones son afirmaciones de la propia plataforma.
Capital en riesgo. La mayoría de las startups fracasan; las estimaciones son afirmaciones de la propia plataforma. Las participaciones son difíciles de vender antes de una salida.
¿Invertiría la IA?
IA 58 MediaNuestra IA da a este proyecto 58 de 100: Media. Cómo funciona la puntuación de la IA
Información, no asesoramiento personalizado de inversión. La puntuación IA valora los documentos que publica la plataforma, puede equivocarse y no predice la rentabilidad.
Análisis de la IA
IABiogenera S.p.A. — Crowdfunding Investor Memo
Biogenera is a Bologna biotech that has spent 17 years developing a new type of cancer drug that switches off a gene (MYCN) which drives some of the most aggressive childhood tumours; it wants to prove the drug in a first human trial and then license it to a large pharmaceutical company.
Sector: Biotech — paediatric oncology, orphan drugs · Stage: Pre-revenue, entering first human trial (Phase I planned Q1 2027) · HQ: Bologna area (Alto Reno Terme / Ozzano dell'Emilia), Italy · Raise: €250K minimum – €5.0M maximum on CrowdFundMe; €469K raised at 26 Aug 2026
Snapshot
|
1 · Is the price fair? 💶 |
3 / 5 — Stretched but arguable. The €90m pre-money sits above the 2025 average for VC-priced biotech Series A rounds (≈ $79M, Qubit Capital) and below the $150–300M range recorded for Phase 1–2 biotechs (Baybridge Bio) — but those are institutional rounds with stronger investor rights, and Biogenera's price has been set by the company itself across successive crowd rounds (€70m in 2021, €80m in 2024). |
|
2 · Can they reach an exit stage? ⭐ |
AI SCORE 58 / 100 — Average The drug is manufactured to clinical standard and its orphan status is independently confirmed; the biggest gap is money — €0.9m of cash at the end of 2025 against a yearly cash decrease of €1.9m, with the first patient still five months away. |
|
3 · If they do, what could it pay? 🎯 |
Target 5–7x over 4–6 years (stage-standard for a company at this level of funding — the company gives no target of its own). If reached, illustratively 1.5x–4x before fees and future dilution. Method: the disclosed post-money of €95m compared with the next-stage valuations the benchmarks record for biotechs entering or in early trials — $79M Series A average (Qubit Capital, 2026) and $150–400M Series B (Baybridge Bio) — treating dollars and euros as roughly equal for this illustration. The 5–7x target itself would need an equity value of roughly €478m–€668m, above the top of the next-stage valuations we could find on record. These figures do not include dilution from future fundraising rounds, which would reduce an early investor's share and actual returns — see the dilution section for how this works. |
How to read the score
|
85–100 · Excellent |
All key preconditions for reaching an exit stage are evidenced and strong — rare at this stage |
|
70–84 · Good |
Preconditions largely in place, with specific gaps — named in the questions section |
|
50–69 · Average |
Meaningful preconditions missing or weakly evidenced |
|
30–49 · Weak |
Several core preconditions absent, or the evidence points against them |
|
1–29 · Critical |
Fundamental preconditions are not visible in the evidence |
|
What we could check. We verified against public sources four of the five orphan-drug designations (EMA and FDA register numbers quoted in peer-reviewed papers), the two peer-reviewed studies on the drug, the clinical-research partner (CVBF), the CEO's and CFO's backgrounds, the 2021 and 2024 crowd rounds and the live status of this one. The company's own statutory accounts (2023–2025) give the financial picture; the 2025 accounts are a draft dated 31 March 2026 without an audit opinion in the pack. The 2026–2033 projections, the patent list, the licensing talks, today's cash balance and the fairness opinion behind the €90m price rest on the company's word — see the questions section. Your money is locked in. Crowdfunding shares normally cannot be sold early — expect your money to be tied up for several years, until the company is sold, listed or a similar event happens. |
Three answers, one honest note. The valuation-fairness score says whether the entry price is supported by the sector benchmarks we could find. The AI Score is our read on whether the company has the preconditions in place to reach a stage where an exit or return event can happen: it audits readiness on the disclosed evidence, it is not a probability of success, and even companies with every precondition in place fail more often than they succeed — which is why crowdfunding only works as a small part of a diversified portfolio. The potential-returns range is an illustration of what a successful outcome could pay, drawn from named sector benchmarks, not a forecast. Where something was not in the pack we reviewed, it did not lower any score; it appears in the questions list so you can ask the company directly before investing. The listing was reviewed by CrowdFundMe, a crowdfunding platform licensed under EU Regulation 2020/1503, before going live; where a fact could exist outside the pack (interviews, the company's data room, the platform Q&A) we say so rather than assume the worst. Nothing in this memo is a recommendation.
At a glance
|
✅ Three reasons to look closer |
⚠️ Three reasons for caution |
|
|
El análisis completo cubre al prestatario o la empresa, la garantía, el flujo de caja, los riesgos y un veredicto. Inicie sesión para leerlo.
Información, no asesoramiento personalizado de inversión. La puntuación IA valora los documentos que publica la plataforma, puede equivocarse y no predice la rentabilidad.
Preguntar a la IA sobre este proyecto
Inicie sesión para preguntar a la IA sobre los documentos de este proyecto.
Iniciar sesión¿Le gusta este proyecto?
👍 Sí · 0 👎 No · 0
Comentarios · 0
- Aún no hay comentarios.
La plataforma y proyectos similares
Ofrecido en
Proyectos abiertos similares
Kepplair Evolution
Sowefund
- Rentabilidad estimada
- hasta 7×
- estimación de la plataforma
- Valoración
- €60,000,000
Objetivo: €9m
Desde €500
Ver proyecto
Wind Fisher
Sowefund
- Rentabilidad estimada
- hasta 10×
- estimación de la plataforma
- Valoración
- €9,961,800
Objetivo: €600k
Desde €1,000
Ver proyecto
Blumana
Sowefund
- Rentabilidad estimada
- hasta 28×
- estimación de la plataforma
- Valoración
- €2,799,571
Objetivo: €750k
Desde €1,000
Ver proyecto